HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method
- Authors:
- Nazanin Sharifi
- Arash Salmaninejad
- Samira Ferdosi
- Abolfazl Nesaei Bajestani
- Malihe Khaleghiyan
- Mehrdad Asghari Estiar
- Mansour Jamali
- Mohammad Reza Nowroozi
- Abbas Shakoori
-
Affiliations: Department of Medical Genetics, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran 1419733141, Iran, Department of Medical Genetics, Ayatollah Madani Hospital, Gonabad University of Medical Sciences, Gonabad 9698154813, Iran, Department of Medical Genetics, Tehran University of Medical Sciences, Tehran 1471613151, Iran, Department of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran 1471613151, Iran, Uro Oncology Research Center, Tehran University of Medical Sciences, Tehran 1471613151, Iran - Published online on: October 10, 2016 https://doi.org/10.3892/ol.2016.5235
- Pages: 4651-4658
This article is mentioned in:
Abstract
 |
|
Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J and Basaria S: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 24:3979–3983. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM and Rubin MA: TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol. 31:882–888. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kolahdoozan S, Sadjadi A, Radmard AR and Khademi H: Five common cancers in Iran. Arch Iran Med. 13:143–146. 2010.PubMed/NCBI | |
|
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O and Bray F: International variation in prostate cancer incidence and mortality rates. Eur Urol. 61:1079–1092. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, Ng CF and Sung JJ: Global incidence and mortality for prostate cancer: Analysis of temporal patterns and trends in 36 countries. Eur Urol. June 8–2016.(Epub ahead of print). View Article : Google Scholar | |
|
Kallioniemi OP and Visakorpi T: Genetic basis and clonal evolution of human prostate cancer. Adv Cancer Res. 68:225–255. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Boyd LK, Mao X and Lu YJ: The complexity of prostate cancer: Genomic alterations and heterogeneity. Nat Rev Urol. 9:652–664. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, et al: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 59:61–71. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Damaschke N, Yang B, Bhusari S, Svaren J and Jarrard D: Epigenetic susceptibility factors for prostate cancer with aging. The Prostate. 2013.73(16): 1721–1730. View Article : Google Scholar : PubMed/NCBI | |
|
Parent ME and Siemiatycki J: Occupation and prostate cancer. Epidemiol Rev. 23:138–143. 2015. View Article : Google Scholar | |
|
Salmaninejad A, Sadeghi N and Ghadami S: Alterations of KRAS exon 2 codon 12/13 mutation status in prostatic adenocarcinoma; Bioinformatics aspects. Arch Can Res. 4:22016. View Article : Google Scholar | |
|
Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Eeles RA, Al Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, et al: Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 45:385–391, 391e1-2. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N, Kawaguchi T, Tsunoda T, Inazawa J, Kamatani N, Ogawa O, et al: Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet. 42:751–754. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Barbieri CE, Demichelis F and Rubin MA: Molecular genetics of prostate cancer: Emerging appreciation of genetic complexity. Histopathology. 60:187–198. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al: Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 448:595–599. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar-Sinha C, Tomlins SA and Chinnaiyan AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 8:497–511. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Santarius T, Shipley J, Brewer D, Stratton MR and Cooper CS: A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 10:59–64. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Salmaninejad A, Ghadami S, Dizaji MZ, Golchehre Z, Estiar MA, Zamani MR, Ebrahimzadeh-Vesal R, Nowroozi MR and Shakoori A: Molecular characterization of KRAS, BRAF, and EGFR genes in cases with prostatic adenocarcinoma; reporting bioinformatics description and recurrent mutations. Clin Lab. 61:749–759. 2015.PubMed/NCBI | |
|
Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM and Masters JR: Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol. 198:237–244. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Saramäki OR, Tammela TL, Martikainen PM, Vessella RL and Visakorpi T: The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer. 45:639–645. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Saramäki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L and Visakorpi T: Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol. 159:2089–2094. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC, Mihatsch MJ, Kunzelmann K and Bubendorf L: KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene. 26:2525–2534. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ren B, Yu G, Tseng GC, Cieply K, Gavel T, Nelson J, Michalopoulos G, Yu YP and Luo JH: MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene. 25:1090–1098. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang R, Xu J, Saramäki O, Visakorpi T, Sutherland WM, Zhou J, Sen B, Lim SD, Mabjeesh N, Amin M, et al: PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21. 1 and overexpressed in human prostate cancer. Cancer Res. 64:1589–1594. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Saramäki OR, Savinainen KJ, Nupponen NN, Bratt O and Visakorpi T: Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet Cytogenet. 128:31–34. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, et al: Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006. J Clin Oncol. 31:1726–1731. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G and Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17:2639–2648. 1999.PubMed/NCBI | |
|
Poovassery JS, Kang JC, Kim D, Ober RJ and Ward ES: Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer. Int J Cancer. 137:267–277. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Rao K, Gaughan L, Robson C and McCracken S: The role of the HER2 and HER3 in prostate cancer and their potential as therapeutic targets. Eur J Cancer. 61:S177–S178. 2016. View Article : Google Scholar | |
|
Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ, Park ES, Kim MK, Yoo JH and Lee SW: Correlation of AR, EGFR, and HER2 expression levels in prostate cancer: Immunohistochemical analysis and chromogenic in situ hybridization. Cancer Res Treat. 44:50–56. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Reese DM, Small EJ, Magrane G, Waldman FM, Chew K and Sudilovsky D: HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol. 116:234–239. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z and Kurzrock R: HER2 expression status in diverse cancers: Review of results from 37,992 patients. Cancer Metastasis Rev. 34:157–164. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Yamanaka Y, Friess H, Kobrin MS, Büchler M, Kunz J, Beger HG and Korc M: Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol. 24:1127–1134. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Nuciforo PG, Pellegrini C, Fasani R, Maggioni M, Coggi G, Parafioriti A and Bosari S: Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol. 34:639–645. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Salmaninejad A, Estiar MA, Gill RK, Shih JH, Hewitt S, Jeon HS, Fukuoka J, Shilo K, Shakoori A and Jen J: Expression analysis of p16, c-Myc, and mSin3A in non-small cell lung cancer by computer aided scoring and analysis (CASA). Clin Lab. 61:549–559. 2015.PubMed/NCBI | |
|
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY, Penault-Llorca F, van de Vijver M and Viale G: HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol. 27:4–18. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z and Orr-Urtreger A: Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 62:6803–6807. 2002.PubMed/NCBI | |
|
Sattler HP, Lensch R, Rohde V, Zimmer E, Meese E, Bonkhoff H, Retz M, Zwergel T, Bex A, Stoeckle M and Wullich B: Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate. 45:207–215. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Elo JP and Visakorpi T: Molecular genetics of prostate cancer. Ann Med. 33:130–141. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Edwards J, Mukherjee R, Munro AF, Wells AC, Almushatat A and Bartlett JM: HER2 and COX2 expression in human prostate cancer. Eur J Cancer. 40:50–55. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Edwards J, Krishna NS, Witton CJ and Bartlett JM: Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res. 9:5271–2581. 2003.PubMed/NCBI | |
|
Nupponen NN, Kakkola L, Koivisto P and Visakorpi T: Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol. 153:141–148. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lass U, Hartmann C, Capper D, Herold-Mende C, von Deimling A, Meiboom M and Mueller W: Chromogenic in situ hybridization is a reliable alternative to fluorescence in situ hybridization for diagnostic testing of 1p and 19q loss in paraffin-embedded gliomas. Brain Pathol. 23:311–318. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Perez T, Blondin B, Du J, Liu P, Escarzaga D, et al: Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment. BMC Cancer. 14:1292014. View Article : Google Scholar : PubMed/NCBI | |
|
Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO and Couturier J: Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer. 88:1587–1591. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB, Rubin MA, van der Kwast T, Amin M and Epstein JI: Contemporary grading for prostate cancer: Implications for patient care. Eur Urol. 63:892–901. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F and Mottet N: European Association of Urology: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent - update 2013. Eur Urol. 65:124–137. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ and Isola J: Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 157:1467–1472. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Lennartz M, Minner S, Brasch S, Wittmann H, Paterna L, Angermeier K, Öztürk E, Shihada R, Ruge M, Kluth M, et al: The combination of DNA ploidy status and PTEN/6q15 deletions provides strong and independent prognostic information in prostate cancer. Clin Cancer Res. 22:2802–2811. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, et al: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res. 8:3438–3444. 2002.PubMed/NCBI | |
|
Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, Wroclawski ER and Del Giglio A: Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis. J Urol. 184:842–850. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Qi M, Yang X, Zhang F, Lin T, Sun X, Li Y, Yuan H, Ren Y, Zhang J, Qin X and Han B: ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PLoS One. 9:e849592014. View Article : Google Scholar : PubMed/NCBI | |
|
Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA and Muraca PJ: HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol. 28:827–833. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, et al: KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer. 133:1259–1265. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Park YS, Hwang HS, Park HJ, Ryu M-H, Chang H-M, Yook JH, Kim BS, Jang SJ and Kang YK: Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: Which scoring system should we use? Hum Pathol. 43:413–422. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Jacquemier J, Spyratos F, Esterni B, Mozziconacci M-J, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, et al: SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: A multicenter experience based on 840 cases. BMC Cancer. 13:3512013. View Article : Google Scholar : PubMed/NCBI | |
|
Horii R, Matsuura M, Iwase T, Ito Y and Akiyama F: Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer. Breast Cancer. 21:598–604. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Rosa FE, Santos RM, Rogatto SR and Domingues MA: Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas. Braz J Med Biol Res. 46:207–216. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, et al: Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int. 62:728–734. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R and LaSalle JM: Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 7:395–403. 2001.PubMed/NCBI | |
|
Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD and Muraca PJ: Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer. 79:2162–2170. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R and Noble M: Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol. 150:126–131. 1993.PubMed/NCBI | |
|
Mark HF, Feldman D, Das S, Kye H, Mark S, Sun CL and Samy M: Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol. 66:170–178. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Murphy AJ, Hughes CA, Barrett C, Magee H, Loftus B, O'Leary JJ and Sheils O: Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 67:2893–2898. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Savinainen KJ, Saramäki OR, Linja MJ, Bratt O, Tammela TL, Isola JJ and Visakorpi T: Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol. 160:339–345. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Loring P, Cummins R, O'Grady A and Kay EW: HER2 positivity in breast carcinoma: A comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization. Appl Immunohistochem Mol Morphol. 13:194–200. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
van de Vijver M, Bilous M, Hanna W, Hofmann M, Kristel P, Penault-Llorca F and Rüschoff J: Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: An international validation ring study. Breast Cancer Res. 9:R682007. View Article : Google Scholar : PubMed/NCBI | |
|
Elliott K, Hamilton PW and Maxwell P: Fluorescence (FISH) and chromogenic (CISH) in situ hybridisation in prostate carcinoma cell lines: Comparison and use of virtual microscopy. Br J Biomed Sci. 65:167–171. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J and van de Vijver M: Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 132:539–548. 2009. View Article : Google Scholar : PubMed/NCBI |
